Form 4: Tandem Diabetes Care EVP Shannon Hansen Reports Stock Transactions
SEC Form 4 Filing
Shannon Hansen, EVP & Chief Legal Officer of Tandem Diabetes Care, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On February 18, 2025, Shannon Hansen, EVP & Chief Legal Officer of Tandem Diabetes Care, executed transactions involving Tandem Diabetes Care Inc. common stock.
- These transactions included the vesting of 531 and 1,438 restricted stock units (RSUs).
- A portion of the vested shares were withheld by the company to satisfy tax obligations, with 219 and 591 shares withheld respectively at a price of $33.47.
- Following these transactions, Hansen directly owns 12,662 shares of common stock and indirectly owns 1,935 shares through the Shannon M. Hansen Trust.
- She also directly owns 7,185 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, which is common in the medical device industry.
Comparison to Industry Standards
- Executive compensation packages in the medical device industry often include restricted stock units (RSUs) as a form of long-term incentive.
- Companies like Medtronic, Abbott, and Boston Scientific also utilize RSUs in their executive compensation plans.
- The vesting schedules and terms of these RSUs are generally aligned with industry practices to retain and incentivize key personnel.
Stakeholder Impact
- The transactions reported in this filing have a minimal direct impact on shareholders, employees, customers, suppliers, or creditors.
- The filing provides transparency regarding executive compensation and stock ownership, which can be of interest to shareholders.
Key Dates
| Date | Description |
|---|---|
| July 8, 2003 | Date of the Shannon M. Hansen Trust |
| February 15, 2022 | Date of RSU award pursuant to the 2013 Stock Incentive Plan |
| February 15, 2023 | First vesting date (25%) of RSU awarded on February 15, 2022 |
| May 25, 2023 | Date of RSU award pursuant to the 2023 Long-Term Incentive Plan |
| May 15, 2024 | First vesting date (33%) of RSU awarded on May 25, 2023 |
| February 18, 2025 | Date of reported transactions: vesting of RSUs and tax withholding |
| February 20, 2025 | Date of signature on the Form 4 filing |
Keywords
Tandem Diabetes Care, TNDM, Shannon Hansen, restricted stock units, RSU, Form 4, insider trading, stock options, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.